UNSPSC 51293605: Binedaline

This classification denotes an antidepressant agent with the molecular formula C19H23N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3AVG9P140R, chemically known as 1,2-ethanediamine, n,n,n-trimethyl-n-(3-phenyl-1h-indol-1-yl)- but generally known as binedaline, which bears US NIH Compound Identifier 42510. Binedaline most often comes in base and hydrochloride forms. European Medicines Agency schedules Binedaline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05835MIG.

UNSPSC 51293605 Binedaline is a Commodity code representing pharmaceutical products and related drug-management systems that state and local governments procure to support public health and emergency response initiatives. Recent state and local solicitations under this code show purchasing of naloxone (an opioid-overdose reversal medication), safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products distributed through established wholesale channels and government health programs. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). Procurements range from direct-purchase agreements for specific volumes of emergency-response medications to RFPs establishing master contracts with multiple manufacturers and authorized wholesalers serving participating state and local facilities across multiple jurisdictions.

Recent activity concentrates in Texas, Florida, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building and a response deadline of July 26, 2023 (note: the source shows an inconsistent date range). The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program aimed at establishing direct relationships between the state's pharmacy benefit program and pharmaceutical manufacturers. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract effectiveness of July 1, 2026. Vendors typically must comply with FDA requirements, Drug Supply Chain Security Act certification, current Good Manufacturing Practices, and maintain specified insurance coverage including commercial general liability.